Response to : 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles
| Errataetall: |
CommentOn: Ann Rheum Dis. 2020 Sep;79(9):1143-1151. - PMID 32719045 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 82(2023), 5 vom: 24. Mai, Seite e110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smolen, Josef S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological therapy |
|---|
| Anmerkungen: |
Date Completed 14.04.2023 Date Revised 04.05.2023 published: Print-Electronic CommentOn: Ann Rheum Dis. 2020 Sep;79(9):1143-1151. - PMID 32719045 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2021-220164 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32215698X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32215698X | ||
| 003 | DE-627 | ||
| 005 | 20231225181434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2021-220164 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM32215698X | ||
| 035 | |a (NLM)33658235 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smolen, Josef S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response to |b 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Charles |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2023 | ||
| 500 | |a Date Revised 04.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Rheum Dis. 2020 Sep;79(9):1143-1151. - PMID 32719045 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a biological therapy | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a glucocorticoids | |
| 650 | 4 | |a therapeutics | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 82(2023), 5 vom: 24. Mai, Seite e110 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2023 |g number:5 |g day:24 |g month:05 |g pages:e110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2021-220164 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2023 |e 5 |b 24 |c 05 |h e110 | ||